Discovery of novel immunostimulants by dendritic-cell-based functional screening

Blood

Volumn 106, Issue 9, 2005, Pages 3082-3089

  Mizumoto, Norikatsu ^a   Gao, Jimin ^a   Matsushima, Hironori ^a   Ogawa, Yasushi ^a   Tanaka, Hiroaki ^a   Takashima, Akira ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN DERIVATIVE; COLCHICINE; DNA TOPOISOMERASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 1BETA; IRINOTECAN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PODOPHYLLOTOXIN; TOPOTECAN;

ANIMAL CELL; ARTICLE; BIOSENSOR; BONE MARROW CELL; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HUMORAL IMMUNITY; MARKER GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 27644480892     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1161     Document Type: Article

References (56)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
3. La Sala A, Ferrari D, Di Virgilio F, et al. Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol. 2003;73:339-343.
4. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.
5. Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5:825-830.
6. 2 -EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med. 2003;9:744-749.
7. 4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell. 2000;103:757-768.
8. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol. 2004;5:971-974.
9. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
10. Dittmer U, Olbrich AR. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr Opin Microbiol. 2003;6:472-477.
11. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4:1-10.
12. Stockfleth E, Trefzer U, Garcia-Bartels C, et al. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol. 2003;149(suppl 66):53-56.
13. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
14. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
15. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
16. Jakob T, Walker PS, Kreig AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998;161:3042-3049.
17. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28:2045-2054.
18. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.
19. Matsue H, Matsue K, Walters M, et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nat Med. 1999;5:930-937.
20. Timares L, Takashima A, Johnston SA. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc Natl Acad Sci U S A. 1998;95:13147-13152.
21. Godambe SA, Chaplin DD, Takova T, Read LM, Bellone CJ. A novel cis-acting element required for lipopolysaccharide-induced transcription of the murine interleukin-1 gene. Mol Cell Biol. 1995;15:112-119.
22. Matsue H, Yang C, Matsue K, et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol. 2002;169:3555-3564.
23. Matsue H, Edelbaum D, Shalhevet D, et al. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol. 2003;171:3010-3018.
24. Kumamoto T, Huang EK, Paek HJ, et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol. 2002;20:64-69.
25. Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med. 2002;8:358-365.
26. Mizumoto N, Hui F, Edelbaum D, et al. Differential activation profiles of multiple transcription factors during dendritic cell maturation. J Invest Dermatol. 2005;124:718-724.
27. Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361:2235-2242.
28. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells. Nucleic Acids Res. 1996;24:4242-4248.
29. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 1999;5:412-417.
30. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-κB activation by camptothecin: a linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem. 2000;275:9501-9509.
31. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med. 1998;188:2175-2180.
32. Grohmann U, Belladonna ML, Bianchi R, et al. IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunity. 1998;9:315-323.
33. Mann J, Oakley F, Johnson PW, Mann DA. CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-κB, and CBF1. J Biol Chem. 2002;277:17125-17138.
34. Merritt K. Adjuvant action of bacterial endotoxin and colchicine on antibody formation in the hamster. Infect Immun. 1971;4:393-396.
35. Parks DE, Shaller DA, Weigle WO. Induction and mode of action of suppressor cells generated against human gamma globulin, II: effects of colchicine. J Exp Med. 1979;149:1168-1182.
36. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
37. West MA, Wallin RP, Matthews SP, et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science. 2004;305:1153-1157.
38. Dieu M-C, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373-386.
39. Saeki H, Moore AM, Brown MJ, Hwang ST. Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999;162:2472-2475.
40. Aiba S, Katz SI. Phenotypic and functional characteristics of in vivo activated Langerhans cells. J Immunol. 1990;145:2791-2796.
41. Rhodes J. Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol. 2002;130:363-369.
42. Wall ME, Wani MC, Cook CE, Palmer KH. Plant antitumor agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888-3890.
43. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873-14878.
44. Mekori YA, Baram D, Goldberg A, Klajman A. Inhibition of delayed hypersensitivity reactions in mice by colchicine: I, mechanism of inhibition of contact sensitivity in vivo. Cell Immunol. 1989;120:330-340.
45. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
46. Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994-1002.
47. Blocker A, Severin FF, Burkhardt JK, et al. Molecular requirements for bi-directional movement of phagosomes along microtubules. J Cell Biol. 1997;137:113-129.
48. Keller HU, Naef A, Zimmermann A. Effects of colchicine, vinblastine and nocodazole on polarity, motility, chemotaxis and cAMP levels of human polymorphonuclear leukocytes. Exp Cell Res. 1984;153:173-185.
49. Borel JF, Feurer C. Chemotaxis of rabbit macrophages in vitro: inhibition by drugs. Experientia. 1975;31:1437-1439.
50. Pinkston JA, Finch SC. Effect of colchicine on the migration of human lymphocyte subpopulations under agarose. Jpn J Exp Med. 1985;55:201-206.
51. Allardyce RA, Hunt JS, Stewart RJ. A micro macrophage migration inhibition test for the detection of cellular immunity in vitro. J Immunol Methods. 1979;27:9-18.
52. Rosette C, Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-κB. J Cell Biol. 1995;128:1111-1119.
53. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J Biol Chem. 2003;278:7445-7452.
54. Giannoukakis N, Bonham CA, Qian S, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-κB decoy oligodeoxyribonucleotides. Mol Ther. 2000;1:430-437.
55. Yoshimura S, Bondeson J, Brennan FM, Foxwell BM, Feldmann M. Role of NFκB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol. 2001;31:1883-1893.
56. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151-161.